Dec 17, 2019
Alligator Bioscience: First Patient Dosed With ATOR-1017 Developed for Metastasized Cancer
Nov 29, 2019
Alligator Bioscience AB Appoints Chief Operating Officer
Nov 06, 2019
Alligator Bioscience: ATOR-1017 Induces Long-Lasting Immunity - New Preclinical Data to be Presented at SITC 34th Annual Meeting
Oct 24, 2019
Alligator Bioscience AB Interim Report January-September 2019
Jul 31, 2019
Alligator Bioscience Regains Global Rights From Janssen to CD40 Agonistic Antibody, ADC-1013 (JNJ-64457107)
Jul 11, 2019
Alligator Bioscience AB (publ) Interim Report January-June 2019
Jun 18, 2019
Alligator Bioscience Submits Clinical Trial Application for ATOR-1017
May 15, 2019
Alligator Bioscience: ADC-1013 Clinical Phase I Data to be Presented at ASCO
Apr 17, 2019
The Nomination Committee's Proposal for the Annual Shareholders' Meeting in Alligator Bioscience AB (publ)
Apr 17, 2019
Alligator Bioscience AB (publ) Interim Report January-March 2019
Apr 10, 2019
Notice of Annual Shareholders' Meeting in Alligator Bioscience AB (publ)
Apr 10, 2019
Alligator Bioscience to Present New Preclinical Data on ATOR-1015 at PEGS Boston
Apr 02, 2019
Alligator Bioscience: New Preclinical Data for ATOR-1144 Demonstrate Potential for Activation of Both the Innate and the Adaptive Immune System, as well as Direct Anti-tumor Effects
Mar 22, 2019
Alligator Bioscience's Annual Report 2018 Published
Mar 18, 2019
Alligator Bioscience: New Preclinical Data Demonstrate Strong Anti-tumor Effects for the 4-1BB Antibody ATOR-1017
Mar 07, 2019
Alligator Bioscience: First Patient Dosed in Phase I study of ATOR-1015
Feb 14, 2019
Alligator Bioscience AB Year-end Report 2018
Feb 12, 2019
Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update
Jan 29, 2019
Alligator Bioscience Publishes Clinical Phase I Data for ADC-1013 in the International Journal of Cancer
Jan 07, 2019
Alligator Bioscience Launches RUBY(TM), a Novel Concept in Bispecific Antibody Formats